Supriya Lifescience Limited is navigating a measured leadership transition as it confirms the completion of the five-year tenure of two Independent Directors, Dinesh Navnitlal Modi and Dileep Kumar Jain, effective March 24, 2026. The company lauded both directors for their long-standing contributions and the role they played in guiding governance during their tenure, underscoring a steady hand at the helm as the board-driven refresh unfolds.
In a closely watched governance move, the board, at its meeting on February 9, 2026, reconstituted the company’s key committees to ensure continuity and oversight. The Audit Committee and the Nomination and Remuneration Committee will now be led by Hari K. as Chairman, with Dr. Ganapati Dadasaheb Yadav and Dr. Satish Waman Wagh serving as members, alongside Manish Panchal. The updated slate reflects a deliberate alignment of expertise and stewardship as the company moves forward without the two long-serving independent directors.
Further governance detail shows the Stakeholders’ Relationship Committee now comprises Manish Panchal as Chairman, with Dr. Saloni Satish Wagh and Dr. Satish Waman Wagh as members. These shifts are being framed as a normal course in the lifecycle of the board, balancing continuity with fresh oversight as Supriya Lifescience continues to pursue its strategic priorities and maintain strong governance standards.